Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjects

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 6, 2005, Pages 343-348

  Scoppetta, M ^a   Di Gennaro, G ^b   Scoppetta, C ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS NEUROMED   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antidepressant drugs; Emotional lability; Fluoxetine; Paroxetine; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BEHAVIOR CONTROL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MALE; MENTAL INSTABILITY; MOOD DISORDER; NEUROLOGIC DISEASE; OFFENDER; POLICE; SIDE EFFECT; SOCIAL LIFE; SOLDIER;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CRYING; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EMOTIONS; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 31844435143     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002; 5: 415-416.
2. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 2004; 10: 679-685.
3. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatr 1993; 150: 286-293.
4. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand 1998; 98: 455-458.
5. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriat Psychiatry 1999; 14: 681-685.
6. Bogousslavsky J. Emotions, mood and behaviour after stroke. Stroke 2003; 34: 1046-1050.
7. House AO, Hackett ML, Anderson CS, Horrocks JA. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst Rev 2004; CD003690.
8. Iannaccone S, Ferini-Strambi L. Pharmacological treatment of emotional lability. Clin Neuropharmacol 1996; 19: 532-535.
9. Muller U, Murai T, Bauer-Wittmund T, von Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999; 13: 805-811.
10. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998; 10: 453-455.
11. Lane RD, Reiman EM, Bradley MM, et al. Neuroanatomical correlates of pleasant and unpleasant emotion. Neuropsychologia 1997; 35: 1437-1444.
12. Wei Q, Lu XY, Liu L, et al. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. PNAS 2004; 101: 11851-11856.
13. Zhong P, Yan Z. Chronic antidepressant treatment alters serotoninergic regulation of GABA transmission in prefrontal cortical tract neurons. Neuroscience 2004; 129: 65-73.
14. LeDoux JE. Emotion circuits in the brain. Ann Rev Neurosci 2000; 23: 155-184.
15. Pegna AJ, Khateb A, Lazeyras F, Seghier ML. Discriminating emotional faces without primary visual cortices involved the right amygdala. Nature Neurosci 2005; 8: 24-25.
16. Dolcos F, LaBar KS, Cabeza R. Remembering one year later: role of the amygdala and the medial temporal lobe memory system in retrieving emotional memories. PNAS 2005; 102: 2626-2631.
17. Gelfin Y, Gorfine M, Lerer B. Effect of clinical doses of fluoxetine on psychological variables in health volunteers. Am J Psychiatry 1998; 155: 290-292.
18. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998; 155: 373-379.
19. Garcia-Colunga J, Awad JN, Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). PNAS 1997; 94: 2041-2044.
20. Maggi L, Palma E, Miledi R, Eusebi F. Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors. Mol Psychiatry 1998; 3: 350-355.
21. Han ZY, Zou M, Cardona A, Bourgeois JP, Changeux JP, Le Novere N. Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta. J Comp Neurol 2003; 461: 49-60.
22. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 2004; 56: 657-664.
23. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7: 525-535.
24. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Inj 1992; 6: 267-270.